| AOBLX | CLBAX | AOBLX / CLBAX | |
| Total Expense Ratio | 0.93 | 0.58 | 160% |
| Annual Report Gross Expense Ratio | 0.93 | 0.58 | 160% |
| Fund Existence | 35 years | 25 years | - |
| Gain YTD | 12.606 | 7.963 | 158% |
| Front Load | 2% | 4% | 64% |
| Min. Initial Investment | 2500 | 250 | 1,000% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 496M | 285B | 0% |
| Annual Yield % from dividends | 1.59 | 1.80 | 89% |
| Returns for 1 year | 16.70 | 5.93 | 282% |
| Returns for 3 years | 53.57 | 41.26 | 130% |
| Returns for 5 years | 37.28 | 32.92 | 113% |
| Returns for 10 years | 87.67 | 93.63 | 94% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| RRBGX | 189.49 | 1.12 | +0.59% |
| T. Rowe Price Blue Chip Growth R | |||
| TSRPX | 23.36 | N/A | N/A |
| Nuveen Quant Small Cap Equity Premier | |||
| GABPX | 56.81 | -0.15 | -0.26% |
| Goldman Sachs Equity Income P | |||
| FDAGX | 90.63 | -0.61 | -0.67% |
| Fidelity Advisor Consumer Staples A | |||
| RYOIX | 93.54 | -1.10 | -1.16% |
| Rydex Biotechnology Inv | |||